KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Intuitive Surgical (ISRG) Research & Development (2016 - 2026)

Intuitive Surgical has reported Research & Development over the past 18 years, most recently at $361.9 million for Q1 2026.

  • Quarterly Research & Development rose 14.45% to $361.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.4 billion through Mar 2026, up 15.34% year-over-year, with the annual reading at $1.3 billion for FY2025, 14.54% up from the prior year.
  • Research & Development was $361.9 million for Q1 2026 at Intuitive Surgical, up from $352.9 million in the prior quarter.
  • Over five years, Research & Development peaked at $361.9 million in Q1 2026 and troughed at $207.3 million in Q2 2022.
  • The 5-year median for Research & Development is $280.1 million (2024), against an average of $276.3 million.
  • Biggest five-year swings in Research & Development: surged 33.1% in 2022 and later grew 6.55% in 2023.
  • Tracing ISRG's Research & Development over 5 years: stood at $244.1 million in 2022, then grew by 6.55% to $260.1 million in 2023, then increased by 13.3% to $294.7 million in 2024, then increased by 19.75% to $352.9 million in 2025, then grew by 2.55% to $361.9 million in 2026.
  • According to Business Quant data, Research & Development over the past three periods came in at $361.9 million, $352.9 million, and $329.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.